Project Details Solubility of Non-steroidal Anti-inflammatory Drugs in Both Neat Organic Solvents and Organic Solvent Mixtures

Project No.:
2014-006-1-500
Start Date:
01 February 2014
End Date:
01 May 2014
Division Name:
Analytical Chemistry Division
Division No.:
500

Objective

Solubility Data Series; editor-in-chief: Mark Salomon

To compile and evaluate published experimental solubility data for non-steroidal anti-inflammatory drugs (NSAIDs) dissolved in organic solvents and organic solvent mixtures. The solubility behavior of twenty five drugs will be examined.

Description

The volume will review the solubility of non-steroidal anti-inflammatory drugs (NSAIDs) in neat organic solvents and binary organic mixtures. NSAIDs represent a diverse class of drugs and are amongst the most commonly used analgesics for the management of pain and/or inflammation associated with rheumatoid arthritis and osteoarthritis, muscle stiffness and pain due to Parkinson’s disease, muscle injury (tendinitis and bursitis), acute gout, dysmenorrhoea (menstrual pain), dental pain, migraine, and headache. Medical research is still ongoing regarding the potential of NSAIDs for the prevention of colorectal cancer. Clinical trials suggested that celcoxib is very effective in reducing polyp recurrence in individuals who have undergone colorectal polypectomy. An estimated more than 30 million people worldwide use NSAIDs on a daily basis. Sales of diclofenac and ibuprofen account for more than half of the global sales of NSAIDs for osteoarthritis, and in the United States NSAID sales represent a significant fraction of the nonprescription, over-the-counter analgesic market. Side effects associated with chronic, long-term use of NSAIDs include direct and indirect irritation of the gastrointestinal tract (e.g., peptic ulcer disease, stomach bleeding, perforation and obstruction), increased risk of cardiovascular adverse effects (e.g., myocardial infarction and stroke, renal failure (e.g., kidney failure) and rectile dysfunction. Rofecoxb and valdecoxib have been withdrawn from the world market because of their association with cardiovascular risk. Valdecoxib was also withdrawn because of an unexpectedly high number of serious dermatological side effects such as Stevens-Johnson syndrome, which is a potentially deadly skin disease that usually results from a drug reaction.

Progress

> May 2014 – Project completed

IUPAC-NIST Solubility Data Series 102. “Solubility of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Neat Organic Solvents and Organic Solvent Mixtures”, J. Phys. Chem. Ref. Data 43, 023102(2014); https://dx.doi.org/10.1063/1.4869683